摘要:
Disclosed is a method of making 1,1'-oxybis (3-nitro-5-trifluoromethyl)-benzene by heating a nitro benzofluoride compound having the formula ##STR1## where "X" is selected from the group consisting of NO.sub.2, Cl, and F, with an alkali metal fluoride selected from the group consisting of potassium fluoride, cesium fluoride, and mixtures thereof, in an organic solvent in the presence of water. The corresponding diamine, 5,5'-oxybis (3-trifluoromethyl)-benzamine, can be prepared by reducing the benzene compound.
摘要:
Disclosed are bis-meta-benzotrifluoride compounds having the general formula ##STR1## where each A is independently selected from the group consisting of NO.sub.2, NH.sub.2, and NH.sub.3.sup.+ Z.sup.-, Z.sup.- is an anion and B is selected from the group consisting of O, CO, S, SO, and SO.sub.2. The diamine compounds are useful as monomers in making polyimides, polyamide-imides, and polyamides.
摘要:
Disclosed are bis-meta-benzotrifluoride compounds having the general formula ##STR1## where each A is independently selected from the group consisting of NO.sub.2, NH.sub.2, and NH.sub.3.sup.+ Z.sup.-, Z.sup.- is an anion and B is selected from the group consisting of O, CO, S, SO, and SO.sub.2. The diamine compounds are useful as monomers in making polyimides, polyamide-imides, and polyamides.
摘要:
Disclosed is a method of making 1,1'-sulfonylbis[3-nitro-5-(trifluoromethyl) benzene] by reacting dibenzotrifluoride sulfide with at least four equivalents of fuming nitric acid and at least four equivalents of fuming sulfuric acid at a temperature below 20.degree. C., until the sulfide link is oxidized to a sulfone link, then raising the temperature to above 20.degree. C. until the reaction is complete. Also disclosed is the preparation of 1,1'-sulfonylbis[3-nitro-(5-trifluoromethyl) benzenamine] by reducing the benzene compound.
摘要:
Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, or Crohn's disease.
摘要:
Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.
摘要:
A method of inhibiting the growth of a bacterial species in a human or non-human vertebrate employs the antimicrobial (i.e., antibiotic) properties of 5-aminosalicylates. These antimicrobial properties are also employed in an antimicrobial method of inhibiting the growth of a bacterial species in a foodstuff and in foodstuffs containing a 5-aminosalicylate compound. Pharmaceutical compositions, foodstuffs, food containers, food-handling implements, cleansers, polishes, paints, sprays, soaps, or detergents comprise 5-aminosalicylate compounds, such as mesalamine, sulphasalazine, olsalazine, ipsalazine, salicylazobenzoic acid, balsalazide, or conjugated bile acids, including ursodeoxycholic acid-5-aminosalicylic acid. The present pharmaceutical compositions can be formulated for ingestive, colonic, or topical non-systemic delivery systems or for any systemic delivery systems. Formulation can be for human or veterinary administration. Using the method and pharmaceutical preparations the growth of bacterial species, such as Clostridium perfringens, Clostridium difficile, Clostridium botulinum, and Clostridium tetani can be inhibited.
摘要:
p-Trifluoromethyl benzaldehydes are prepared by the catalytic reduction reaction of p-trifluoromethyl benzonitriles with hydrogen in an aqueous formic acid media in the presence of a nickel/aluminum alloy catalyst.
摘要:
4,4-dihalohexahydrophthalic anhydrides of the formula ##STR1## where Y is chlorine or fluorine, are prepared by the reaction of hydrogen fluoride with 4-chlorotetrahydrophthalic anhydride.The 4,4-dihalohexahydrophthalic anhydrides of this invention can be dehydrohalogenated by reaction with basic alumina to prepare a mixture of 4-fluorotetrahydrophthalic anhydride isomers of the formula ##STR2## The 4-fluorotetrahydrophthalic anhydrides can then be dehydrogenated by reaction with a dehydrogenation catalyst to prepare 4-fluorophthalic anhydride.
摘要:
A pharmaceutical composition includes a preparation of virus-like particles (VLPs) obtained from the gastrointestinal tract of a subject and a pharmaceutically-acceptable carrier. The VLPs can include bacteriophages, eukaryotic viruses, or gene transfer agents. A VLP composition may be administered to a subject having, or at risk of having dysbiosis, in an amount effective to amelio-rate at least one symptom or clinical sign of dysbiosis. A VLP composition also may be administered to a subject in preparation for administering a source of bacteria, to improve the receptivity of subject's gut to source of bacteria.